NEW YORK (GenomeWeb) – Cancer Genetics has priced a public offering of 3 million shares of its common stock at $4 per share, the company said today.

The firm is also offering five-year warrants to purchase 3 million shares of common stock at an exercise price of $5 per share. Cancer Genetics has granted the underwriters a 45-day option to purchase up to 450,000 additional shares of common stock and/or warrants.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.